Continuous wearable monitoring reduces time with low oxygen after surgery, study finds
medicalxpress - Patients continuously monitored after surgery experienced significantly less time with dangerously low oxygen levels compared to those monitored using routine spot checks, a new study from Wake Forest University School of Medicine found.
AI Summary: An HCA Florida hospital has named a new chief financial officer as part of a leadership shakeup aimed at stabilizing operations and tightening financial oversight. The appointment signals management’s focus on fiscal discipline and strategic planning amid ongoing industry pressures—because nothing says “confidence” like swapping out the person who signs the checks.
Two States Sue Cord Blood Bank Over False Advertisements
Sarah Kliff and Azeen Ghorayshi / nytimes - The attorneys general of Texas and Arizona contend that Cord Blood Registry, which stores umbilical cord cells, profited from misleading new parents.
AI Summary: Two state attorneys general filed lawsuits alleging a cord‑blood bank made false or misleading claims about the future therapeutic value of stored units. The actions seek consumer remedies and penalties, challenging marketing that regulators say may have led families to pay for services based on overstated promises about potential medical uses.
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…
AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.
Cencora acquiring EyeSouth Partners' retina business for $1.1B
fiercehealthcare - EyeSouth Partners' retina specialists will join Cencora's Retina Consultants of America, a management services organization that already boasts the country's largest network of retina centers.
AI Summary: Cencora has agreed to acquire EyeSouth Partners’ retina business for roughly $1.1 billion, strengthening its position in specialty ophthalmology services. The deal transfers a network of retinal care assets and aims to integrate retina-focused clinical operations and distribution under Cencora’s broader eye‑care strategy.